drugset / Trial / NCT00002390

A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients

NCT00002390

Phase 2 Completed Glaxo Wellcome
Double-blindTreatment

Summary

The purpose of this study is to see if giving 1592U89 to HIV-infected patients is safe and effective in lowering viral load (level of HIV in the blood) and raising the level of CD4 cells (cells of the body that help fight infection).

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Abacavir Other / unclassified 300 mg